{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-002165","form_type":"8-K","ticker":"CTMX","cik":"0001501989","company_name":"CytomX Therapeutics, Inc.","filed_at":"2025-01-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.813017+00:00","generated_at":"2026-05-28T10:34:42.884932+00:00","sec_items":["2.05"],"event_type":"other_material","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"CytomX to cut ~40% of workforce, focus on CX-2051, extend cash runway","bullets":["Workforce reduction of ~40%, primarily affecting G&A and non-partnered research staff, substantially complete in Q1 2025.","Estimated restructuring charges of $5M to $6M, mostly severance, recorded in Q1 2025.","Cash payments of ~$5M starting Q1 2025; cash runway extended into Q2 2026.","Company to prioritize CX-2051 (EpCAM PROBODY ADC) and support research collaborations."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-002165","json":"https://secwatch.observer/filing/0001193125-25-002165.json","markdown":"https://secwatch.observer/filing/0001193125-25-002165.md","text":"https://secwatch.observer/filing/0001193125-25-002165.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1501989/000119312525002165/0001193125-25-002165-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1501989/000119312525002165/d909597d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T10:34:42.884932+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}